Literature DB >> 9101641

Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls.

F Yamanobe1, S Mochida, A Ohno, K Ishikawa, K Fujiwara.   

Abstract

The expression of tissue factor pathway inhibitor (TFPI) was investigated in sinusoidal endothelial cells in the liver and endothelial cells in the lung. Northern blot analysis revealed that TFPI mRNA was expressed in the lung, but minimal in the liver. Also, immunohistochemical examination showed that TFPI was not expressed on the sinusoidal endothelial cells in contrast to marked expression on endothelial cells in the lung, suggesting that anticoagulant activity to inhibit blood coagulation induced by tissue factor is reduced in the hepatic sinusoids compared to the microvessels of other organs. When recombinant human TFPI was intravenously injected in rats, it disappeared rapidly from the circulation, but was detected by electron microscopy on the surface of sinusoidal endothelial cells and microvilli of hepatocytes in the space of Disse. In these rats, the TFPI reappeared in the circulation following an intravenous injection of heparin sodium with reduced immunohistochemical staining of the TFPI on hepatic sinusoidal walls. It is concluded that exogenous TFPI can increase anticoagulant activity on the hepatic sinusoidal walls by binding to heparinoids on the cell surface. It may act effectively even in the hepatic sinusoids with damaged endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101641     DOI: 10.1016/s0049-3848(97)00038-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2.

Authors:  S S Lakka; S D Konduri; S Mohanam; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Authors:  Douglas A Simonetto; Hui-yin Yang; Meng Yin; Thiago M de Assuncao; Jung Hee Kwon; Moira Hilscher; Shuchong Pan; Liu Yang; Yan Bi; Arthur Beyder; Sheng Cao; Robert D Simari; Richard Ehman; Patrick S Kamath; Vijay H Shah
Journal:  Hepatology       Date:  2015-01-05       Impact factor: 17.425

3.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

4.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27

Review 5.  Indications and criteria for liver transplantation for fulminant hepatic failure.

Authors:  Kenji Fujiwara; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

6.  Antithrombin III injection via the portal vein suppresses liver damage.

Authors:  Masayuki Miyazaki; Masaki Kato; Masatake Tanaka; Kosuke Tanaka; Shinichiro Takao; Motoyuki Kohjima; Tetsuhide Ito; Munechika Enjoji; Makoto Nakamuta; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.